GlassScriptPhysician profile
Jisoo Lee
NPI 1891456885
$42,669.95
in general payments reported to CMS, 2019-2025
41 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,683 · 2023: $5,691 · 2024: $8,907 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $4,255 · Consulting Fee: $1,007 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,332.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,150.00 |
| Travel and Lodging | $4,254.81 |
| Consulting Fee | $1,006.64 |
| Education | $243.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $19,090.51 | 2022-2025 | Nuplazid |
| Abbvie INC. | $5,464.30 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $2,456.77 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $2,218.96 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbott Laboratories | $1,914.72 | 2022-2025 | Infinity, Proclaim, Octrode |
| Neurocrine Biosciences, INC. | $1,785.21 | 2022-2025 | Ingrezza, Ongentys |
| Medtronic, INC. | $1,523.22 | 2023-2025 | Percept PC Brainsense |
| Boston Scientific Corporation | $1,433.85 | 2023-2025 | General - Dbs |
| Livanova USA, INC. | $1,019.33 | 2022 | |
| Mdd US Operations, LLC | $728.14 | 2022-2025 | Gocovri, Qelbree, Gocovri |
| Jazz Pharmaceuticals INC. | $497.59 | 2022-2023 | |
| Sk Life Science, INC. | $475.15 | 2022-2023 | Xcopri |
| Kyowa Kirin, INC. | $454.94 | 2022-2025 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $453.66 | 2023-2025 | Dysport |
| Lilly USA, LLC | $365.22 | 2022-2025 | Emgality, Reyvow, Kisunla |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jisoo Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.